According to the strategic alliance, both the organizations will jointly advance the ongoing development of AB-16B5 and distribute the downstream economics on an equal basis in territories outside Russia and the CIS states on completion of the initial clinical study.
Alethia president and CEO Yves Cornellier said, "Like Alethia, IBC Generium is dedicated to improving the treatments available to cancer patients and is committing significant resources to develop innovative biological therapeutics including AB-16B5."
The initial clinical study will be conducted in Canada using the upfront cash payment and R&D funding that Alethia obtains.
For right to an exclusive license for Russia and the CIS states, IBC Generium will have to pay development milestones and royalties to Alethia.
IBC Generium chief business officer Daniil Talyanskiy said, "EMT is a key contributor to both tumor invasion and the emergence of resistance to many cancer therapies."
Additional financial details have not been revealed.